Transrectal Ultrasound

Transrectal ultrasound (TRUS) is covered for specific diagnostic and treatment-planning indications involving the prostate, seminal vesicles, rectum, anal canal, and perirectal tissues—notably for prostate cancer staging, post-treatment rising PSA evaluation, guidance for interstitial radioelements, and selected rectal/anal disease staging and abscess/fistula evaluation. TRUS is not covered for asymptomatic screening, confirmatory studies providing no new clinical information, benign lesion evaluation except as listed, or solely for family history; documentation of clinical findings, relevant testing (e.g., PSA, bone scan), planned procedures, and treatment necessity is required for coverage.

"Transrectal ultrasound (TRUS) is covered for clinical staging of proven prostate cancer when radical prostatectomy or radiation therapy is being considered."

Sign up to see full coverage criteria, indications, and limitations.